February 19, 2018 — The Detroit Medical Center’s (DMC) interventional cardiology team at Heart Hospital recently became ...
Stents Drug Eluting
This channel includes news and new technology innovations for drug eluting stents (DES). These drug coated stents were developed to solve a frequent problem with bare metal stents, which can cause neointimal hyperplasia (scar tissue growth) in some patients. The antiproliferative drugs used on DES prevent the growth of tissue. One downside of DES is the requirement for patients to take long-term antiplatelet therapy to prevent the possible formation of clots on these stents. Newer generation DES use technologies help the vessels heal faster, which may allow reduce the duration of dual antiplatelet therapy (DAPT), or use a single drug, usually eliminating aspirin. This section includes news for both metallic and bioresorbable drug-eluting stents and related clinical trial data.
February 13, 2018 — Abbott announced the first patient has been enrolled in a clinical trial evaluating 28 days of dual ...
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS-2 ...
January 25, 2018 – Elixir Medical Corporation, a leader in the development of breakthrough adaptive remodeling ...
![The Abbott Absorb Bioresorbable Vascular Scaffold (BVS) bioabsorbable stent.](/sites/default/files/styles/content_feed_large/public/field/image/Abbott_Absorb_BVS_bioresorbable_stent_on_balloon.jpg?itok=o3TVsbbO)
There was no shortage of interest in bioresorbable stent technologies at the many sessions offered on this topic or ...
December 13, 2017 — Cordis, a Cardinal Health company, and Medinol recently announced U.S. Food and Drug Administration ...
November 24, 2017 – During a late-breaking session at the European Society of Cardiology (ESC) 2017 meeting, presented ...
November 10, 2017 — Cordis, a Cardinal Health company, recently unveiled a comprehensive interventional cardiology portf ...
November 9, 2017 — Abbott received European CE mark for Xience Sierra, the newest generation of the company's Xience ...
![OCT comparison between the Combo vs. Xience stents in the HARMONEE study.](/sites/default/files/styles/content_feed_large/public/field/image/OCT%20CoreLab-images_HARMONEE-Study.jpg?itok=WwhNp_-I)
November 8, 2017 – New results from the HARMONEE Japan/U.S. Registration Trial, reported by in a first report ...
November 6, 2017 — The first trial to evaluate the safety of dual antiplatelet therapy (DAPT) for less than 12 months ...
November 6, 2017 — Elderly patients undergoing percutaneous coronary intervention (PCI) often receive bare-metal stents ...
November 3, 2017 — Biotronik's Orsiro drug-eluting stent (DES) demonstrated high long-term safety and clinical ...
November 1, 2017 — OrbusNeich reported results from the REDUCE trial in the Late-Breaking Clinical Trial session at the ...